<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652860</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582297</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0072</secondary_id>
    <secondary_id>1021-01</secondary_id>
    <nct_id>NCT00652860</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery</brief_title>
  <official_title>Chemotherapy, Irradiation, and Surgery for Function-Preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and GM-CSF; Aerosol GM-CSF During Preoperative Irradiation and Postoperatively</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. GM-CSF may stimulate&#xD;
      the immune system in different ways and stop tumor cells from growing. GM-CSF, given by&#xD;
      inhalation, may interfere with the growth of tumor cells and prevent metastases from forming.&#xD;
      Radiation therapy uses high energy x rays to kill tumor cells. Giving combination&#xD;
      chemotherapy together with radiation therapy and GM-CSF before surgery may make the tumor&#xD;
      smaller and reduce the amount of normal tissue that needs to be removed. Giving these&#xD;
      treatments after surgery may kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with radiation therapy and GM-CSF before and after surgery works in treating patients with&#xD;
      stage III soft tissue sarcoma that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate 2-year pulmonary metastatic progression rates in patients with primary&#xD;
           high-grade extremity soft tissue sarcoma who have received preoperative I-MAP, plus&#xD;
           aerosol GM-CSF, plus irradiation with concomitant MAP followed by post-operative aerosol&#xD;
           GM-CSF.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate survival of these patients.&#xD;
&#xD;
        -  To evaluate time to progression in these patients.&#xD;
&#xD;
        -  To evaluate toxicity in these patients.&#xD;
&#xD;
        -  To evaluate tumor response in these patients.&#xD;
&#xD;
      Translational&#xD;
&#xD;
        -  To observe and describe sequentially before treatment, after treatment, and after&#xD;
           recovery from treatment the frequency of skin test anergy and cellular immunity in&#xD;
           extremity soft tissue sarcoma receiving systemic GM-CSF preoperatively and aerosol&#xD;
           GM-CSF as part of both preoperative and postoperative treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Neoadjuvant treatment: Patients receive ifosfamide IV over 2 hours on days 0 and 1 and&#xD;
           cisplatin IV over 4 hours, mitomycin IV and doxorubicin IV on day 1. Treatment repeats&#xD;
           every 28 days for 2 courses in the absence of disease progression or unacceptable&#xD;
           toxicity. Patients also receive sargramostim (GM-CSF) subcutaneously (SC) every 12 hours&#xD;
           on days -6 to -3, 2-14, and 22-25. Beginning on day 84 patients also undergo&#xD;
           radiotherapy once daily, five days a week, continuing for five weeks. Patients also&#xD;
           receive GM-CSF SC twice daily on days -3 and 2 -15 and aerosol GM-CSF twice daily on&#xD;
           days 85 - 91, 99 -105, and 113 - 119.&#xD;
&#xD;
        -  Chemoradiotherapy: Beginning 4 weeks after completion of neoadjuvant chemotherapy,&#xD;
           patients undergo radiotherapy (RT) once daily, 5 days a week, for 5 weeks. Patients also&#xD;
           receive aerosolized GM-CSF twice daily on days 2-8, 16-22, and 30-38 and mitomycin C IV,&#xD;
           doxorubicin hydrochloride IV, and cisplatin IV over 2 hours on days 1 and 29.&#xD;
&#xD;
        -  Surgery: Four weeks after completion of chemotherapy, patients undergo surgery. Patients&#xD;
           may also undergo intraoperative RT electron boost or intraoperative high-dose&#xD;
           brachytherapy.&#xD;
&#xD;
        -  Adjuvant treatment: Beginning 4 weeks after surgery, patients receive aerosol GM-CSF&#xD;
           twice daily on days -7, 15-21, 35-42, 56-63, and 77-84. Some patients may undergo&#xD;
           external beam RT 2-4 weeks after surgery.&#xD;
&#xD;
      Blood samples are collected at baseline and at 4 and 14 weeks after surgery. Samples are&#xD;
      tested for NY-ESO-1 by staining, for T-cell subset by flow cytometry, and for autologous&#xD;
      lymphocyte proliferation. Patients may also be tested for delayed-type hypersensitivity and&#xD;
      skin test anergy.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year, every 4&#xD;
      months for 1 year, every 6 months for 2 years, and at 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary metastatic progression-free rate at 2 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as per NCI CTC Version 2.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response every 4 weeks during treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aerosol sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunological diagnostic method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>multimodality therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intraoperative radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>selective external radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary soft tissue sarcoma&#xD;
&#xD;
               -  Sarcoma must be of the extremity or limb girdle origin&#xD;
&#xD;
               -  No metastatic disease&#xD;
&#xD;
               -  High-grade&#xD;
&#xD;
          -  Must be a candidate for preoperative irradiation for potential limb-sparing surgery&#xD;
&#xD;
          -  Must not have any of the following:&#xD;
&#xD;
               -  Embryonal rhabdomyosarcoma&#xD;
&#xD;
               -  Extraosseous Ewing sarcomas&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0 - 2&#xD;
&#xD;
          -  WBC ≥ 3,500/μL OR granulocyte count ≥1,500/μL&#xD;
&#xD;
          -  Platelets ≥150,000/μL&#xD;
&#xD;
          -  Direct-reacting bilirubin ≤ 0.3 mg/dL&#xD;
&#xD;
          -  Creatinine ≤1.2 times the upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Significant infection&#xD;
&#xD;
          -  Active heart disease including any of the following:&#xD;
&#xD;
               -  Myocardial infarction in the past 3 months&#xD;
&#xD;
               -  Symptomatic coronary artery insufficiency&#xD;
&#xD;
               -  First-degree heart block&#xD;
&#xD;
               -  Clinical history of congestive heart failure&#xD;
&#xD;
          -  Symptomatic pulmonary disease.&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Okuno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Scott Okuno, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>lung metastases</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

